Voyager Therapeutics officer files initial holdings
Voyager Therapeutics, Inc. Principal Accounting Officer Amy Quinlan filed an initial statement of beneficial ownership.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Voyager Therapeutics, Inc. Principal Accounting Officer Amy Quinlan filed an initial statement of beneficial ownership. She directly holds 36,749 shares of common stock and two stock option awards covering 28,500 shares at $3.68 per share and 50,000 shares at $5.28 per share.
The options, issued under the company’s 2015 and 2025 stock plans, vest over four years on specified schedules, with each restricted stock unit representing one share of common stock upon vesting.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Quinlan Amy
Role
Principal Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 78,500 contracts (Direct);
Common Stock — 36,749 shares (Direct)
Footnotes (3)
- F1. Includes shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan") and the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan") that vest periodically. Each RSU represents the right to receive one share of common stock upon vesting.
- F2. This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date, January 13, 2025. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting on the one-year anniversary of the vesting commencement date, and an additional 1/36th of the shares of common stock underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.
- F3. This stock option was issued pursuant to the 2025 Plan. The vesting commencement date of the option is the grant date, February 06, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting on the first month anniversary of the vesting commencement date, and an additional 1/48th of shares underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.
Key Figures
Direct common shares: 36,749 shares
Option at $3.68: 28,500 underlying shares at $3.68/share
Option at $5.28: 50,000 underlying shares at $5.28/share
3 metrics
Direct common shares
36,749 shares
Beneficial ownership reported on Form 3
Option at $3.68
28,500 underlying shares at $3.68/share
Stock Option (Right to Buy), expiration 2036-02-06
Option at $5.28
50,000 underlying shares at $5.28/share
Stock Option (Right to Buy), expiration 2035-01-13
Key Terms
restricted stock units ("RSUs"), 2015 Stock Option and Incentive Plan, 2025 Stock Incentive Plan, Stock Option (Right to Buy), +1 more
5 terms
restricted stock units ("RSUs") financial
"Includes shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2015 Stock Option and Incentive Plan financial
"awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan..."
2025 Stock Incentive Plan financial
"and the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan") that vest periodically."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting commencement date financial
"The vesting commencement date of the option is the grant date, January 13, 2025."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 for Voyager Therapeutics (VYGR) show for Amy Quinlan?
The Form 3 shows Amy Quinlan, Principal Accounting Officer, initially reporting 36,749 Voyager Therapeutics common shares plus two stock option grants. These options cover 28,500 and 50,000 underlying shares, forming part of her equity-based compensation and aligning her interests with shareholders.
What stock options are reported for Amy Quinlan in the Voyager Therapeutics (VYGR) Form 3?
Amy Quinlan reports two stock option positions: one for 28,500 underlying common shares at a $3.68 exercise price and another for 50,000 underlying shares at a $5.28 exercise price. Both were granted under Voyager’s equity incentive plans with four-year vesting schedules tied to continued service.
Under which plans were Amy Quinlan’s Voyager Therapeutics (VYGR) equity awards granted?
Her equity awards were granted under the Voyager Therapeutics 2015 Stock Option and Incentive Plan and the 2025 Stock Incentive Plan. These plans govern terms such as vesting schedules, exercise rights, and restricted stock unit treatment, linking long-term compensation to ongoing employment and company performance.
How do Amy Quinlan’s restricted stock units (RSUs) work at Voyager Therapeutics (VYGR)?
Each restricted stock unit represents the right to receive one Voyager Therapeutics common share upon vesting. The RSUs were awarded under the 2015 and 2025 stock plans and vest periodically, meaning additional shares will be delivered over time as vesting conditions based on continued service are satisfied.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates